# Bruker Corp: overview

BRKR · Nasdaq · CIK 1109354 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/brkr.md) · [Financials](/companies/brkr/financials.md) · [Filings](/companies/brkr/filings.md) · [Insiders](/companies/brkr/insiders.md)

Latest reported revenue: [$838.5m](/filings/0001193125-26-335226.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335226).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [864](/filings/0001193125-25-267049.md) | [980 d](/filings/0001193125-26-082523.md) | [801](/filings/0001193125-26-211889.md) | [797](/filings/0001193125-26-335226.md) | [861](/filings/0001193125-25-267049.md) | [977 d](/filings/0001193125-26-082523.md) | [823](/filings/0001193125-26-211889.md) | [839](/filings/0001193125-26-335226.md) |
| Gross margin | % | [48.4%](/filings/0001193125-25-267049.md) | [50.4% d](/filings/0001193125-26-082523.md) | [48.8%](/filings/0001193125-26-211889.md) | [44.9%](/filings/0001193125-26-335226.md) | [44.1%](/filings/0001193125-25-267049.md) | [46.0% d](/filings/0001193125-26-082523.md) | [46.1%](/filings/0001193125-26-211889.md) | [49.6%](/filings/0001193125-26-335226.md) |
| Operating margin | % | [7.9%](/filings/0001193125-25-267049.md) | [7.4% d](/filings/0001193125-26-082523.md) | [4.0%](/filings/0001193125-26-211889.md) | [1.5%](/filings/0001193125-26-335226.md) | [(6.0%)](/filings/0001193125-25-267049.md) | [7.8% d](/filings/0001193125-26-082523.md) | [1.2%](/filings/0001193125-26-211889.md) | [(7.8%)](/filings/0001193125-26-335226.md) |
| Net margin | % | [4.7%](/filings/0001193125-25-267049.md) | [1.4% d](/filings/0001193125-26-082523.md) | [2.2%](/filings/0001193125-26-211889.md) | [1.0%](/filings/0001193125-26-335226.md) | [(6.9%)](/filings/0001193125-25-267049.md) | [2.7% d](/filings/0001193125-26-082523.md) | [1.7%](/filings/0001193125-26-211889.md) | [(6.2%)](/filings/0001193125-26-335226.md) |
| Diluted EPS | $ per share | [0.27](/filings/0001193125-25-267049.md) | not reported | [0.11](/filings/0001193125-26-211889.md) | [0.05](/filings/0001193125-26-335226.md) | [(0.41)](/filings/0001193125-25-267049.md) | not reported | [0.02](/filings/0001193125-26-211889.md) | [(0.41)](/filings/0001193125-26-335226.md) |
| Free cash flow | $m | [5.8 d](/filings/0001193125-25-267049.md) | [153 d](/filings/0001193125-26-082523.md) | [39.0](/filings/0001193125-26-211889.md) | [(149) d](/filings/0001193125-26-335226.md) | [(54.1) d](/filings/0001193125-25-267049.md) | [207 d](/filings/0001193125-26-082523.md) | [47.0](/filings/0001193125-26-211889.md) | [(106) d](/filings/0001193125-26-335226.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,418](/filings/0000950170-24-023038.md) | [2,531](/filings/0000950170-25-030897.md) | [2,965](/filings/0001193125-26-082523.md) | [3,366](/filings/0001193125-26-082523.md) | [3,437](/filings/0001193125-26-082523.md) |
| Gross margin | % | [50.0%](/filings/0000950170-24-023038.md) | [51.6%](/filings/0000950170-25-030897.md) | [51.0%](/filings/0001193125-26-082523.md) | [49.0%](/filings/0001193125-26-082523.md) | [45.9%](/filings/0001193125-26-082523.md) |
| Operating margin | % | [17.1%](/filings/0000950170-24-023038.md) | [17.1%](/filings/0000950170-25-030897.md) | [14.7%](/filings/0001193125-26-082523.md) | [7.5%](/filings/0001193125-26-082523.md) | [2.0%](/filings/0001193125-26-082523.md) |
| Net margin | % | [11.5%](/filings/0000950170-24-023038.md) | [11.7%](/filings/0000950170-25-030897.md) | [14.4%](/filings/0001193125-26-082523.md) | [3.4%](/filings/0001193125-26-082523.md) | [(0.3%)](/filings/0001193125-26-082523.md) |
| Diluted EPS | $ per share | [1.81](/filings/0000950170-24-023038.md) | [1.99](/filings/0000950170-25-030897.md) | [2.90](/filings/0001193125-26-082523.md) | [0.76](/filings/0001193125-26-082523.md) | [(0.15)](/filings/0001193125-26-082523.md) |
| Free cash flow | $m | [190](/filings/0000950170-24-023038.md) | [145](/filings/0000950170-25-030897.md) | [243](/filings/0001193125-26-082523.md) | [136](/filings/0001193125-26-082523.md) | [43.3](/filings/0001193125-26-082523.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/brkr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.22bn | 20,237,425 |  | Added +4,135,622 |
| [Orbis Allan Gray Ltd](/funds/1663865.md) | 2026-06-30 | $1.08bn | 17,940,076 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $686.5m | 11,407,332 |  | Added +226,526 |
| [Pallas Capital Advisors LLC](/funds/1862282.md) | 2026-06-30 | $570.7m | 9,483,978 |  | Added +2,157 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $294.2m | 4,888,290 |  | Added +32,375 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $292.4m | 4,859,252 |  | Added +42,176 |
| [Sculptor Capital LP](/funds/1054587.md) | 2026-06-30 | $278.3m | 4,625,000 |  | Added +1,355,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $241.9m | 4,017,673 |  | Added +108,980 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $194.3m | 3,229,337 |  | Added +310,160 |
| [Sachem Head Capital Management LP](/funds/1582090.md) | 2026-06-30 | $175.4m | 2,915,000 |  | New +2,915,000 |

## Recent filings

[All 1,032 filings](/companies/brkr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:05 ET | [8-K](/filings/0001193125-26-437771.md) | 8.01 Other events | 0001193125-26-437771 |
| 2026-08-14 | 16:15 ET | [8-K](/filings/0001193125-26-352279.md) | 8.01 Other events | 0001193125-26-352279 |
| 2026-08-05 | 16:24 ET | [10-Q](/filings/0001193125-26-335226.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335226 |
| 2026-08-04 | 07:00 ET | [8-K](/filings/0001193125-26-331511.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331511 |
| 2026-07-30 | 16:15 ET | [8-K](/filings/0001193125-26-326150.md) | 8.01 Other events | 0001193125-26-326150 |
| 2026-05-29 | 16:10 ET | [8-K/A](/filings/0001193125-26-248280.md) | 5.07 Shareholder vote results | 0001193125-26-248280 |
| 2026-05-21 | 16:44 ET | [8-K](/filings/0001193125-26-234630.md) | 5.07 Shareholder vote results | 0001193125-26-234630 |
| 2026-05-15 | 16:15 ET | [8-K](/filings/0001193125-26-226767.md) | 8.01 Other events | 0001193125-26-226767 |
| 2026-05-07 | 16:09 ET | [10-Q](/filings/0001193125-26-211889.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211889 |
| 2026-05-06 | 06:30 ET | [8-K](/filings/0001193125-26-207498.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-207498 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-082523.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/16154ed9-8bb2-4234-a647-0d076119af03)

## About the filer

- CIK: 1109354
- Tickers: BRKR, BRKRP
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:07 ET. No prices; not investment advice.